Skip to main content
Premium Trial:

Request an Annual Quote

Third Wave's Q3 Revenues Jump 26 Percent as Net Loss Declines 30 Percent

NEW YORK (GenomeWeb News) — Third Wave Technologies today said third-quarter revenues increases 26 percent as net loss declined 30 percent.
 
Total receipts for the three months ended Sept. 30 increased to $6.6 million from $5.2 million year over year. Molecular diagnosis contributed $5.2 million.
 
R&D expenses on the quarter were up sharply, at $3.5 million compared with $2 million the previous year.
 
Quarterly losses slid 30 percent in the period to $5.2 million from $7.4 million year over year.
 
At the end of the quarter Third Wave had around $33 million in cash, cash equivalents, and short-term investments.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.